{"schema":"rootz.ai/filing-signals/v1","query":{"ticker":"PROF","limit":50},"count":35,"signals":[{"ticker":"PROF","company":"Profound Medical Corp.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"ai_adoption","strength":100,"match_count":15,"context":"al outcomes, side effects and recovery time. *Customizable incision-free ablation of unrivalled variety of prostate indications.* Products TULSA-PRO *Clinical Studies* In March 2014, we completed enrollment and treatment of 30 patients in the TULSA multi-jurisdictional safety and precision study. Based on the trial results, in April 2016, Profound received a CE Certificate of Conformity for the TULSA","filed_date":"2026-03-05","accession":"0001104659-26-024153","full_text":"https://origin.rootz.global/static/filing/0001104659-26-024153.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PROF","company":"Profound Medical Corp.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":117,"context":", anti-bribery laws, environmental laws and privacy and security regulations. Any violation by our employees or other agents could expose us to severe penalties and other consequences that may have a material adverse effect on our business, financial condition and results of operations. | | | | We may not be able to protect our intellectual property rights throughout the world. | | | | We may incur substantial costs as","filed_date":"2026-03-05","accession":"0001104659-26-024153","full_text":"https://origin.rootz.global/static/filing/0001104659-26-024153.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PROF","company":"Profound Medical Corp.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"ai_adoption","strength":100,"match_count":14,"context":"ns interest payable after Maturity at the rate prescribed in such Original Issue Discount Security. Interest Payment Date, when used with respect to any Security, means the Stated Maturity of an installment of interest on such Security. Judgment Currency has the meaning specified in Section 1.14. Lien means any mortgage, pledge, hypothecation, charge, assignment, deposit arrangement, encumbrance, sec","filed_date":"2025-11-13","accession":"0001104659-25-111470","full_text":"https://origin.rootz.global/static/filing/0001104659-25-111470.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PROF","company":"Profound Medical Corp.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":100,"match_count":14,"context":"reates a meaningful incentive for individuals to remain at Profound and not be unreasonably susceptible to recruiting efforts by the Corporations competitors. 11 In determining the base salary of the Named Executive Officers (as defined herein), the Board considered: (i) recruiting and retaining executives critical to the success of Profound and the enhancement of shareholder value; (ii) providing fair and competitive c","filed_date":"2025-04-22","accession":"0001171843-25-002369","full_text":"https://origin.rootz.global/static/filing/0001171843-25-002369.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PROF","company":"Profound Medical Corp.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":115,"context":", anti-bribery laws, environmental laws and privacy and security regulations. Any violation by our employees or other agents could expose us to severe penalties and other consequences that may have a material adverse effect on our business, financial condition and results of operations. | | | | We may not be able to protect our intellectual property rights throughout the world. | | | | We may incur substantial costs as","filed_date":"2025-03-07","accession":"0001410578-25-000300","full_text":"https://origin.rootz.global/static/filing/0001410578-25-000300.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PROF","company":"Profound Medical Corp.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":96,"match_count":12,"context":"could reasonably be expected to interfere with the exercise of the directors independent judgment. If the Chairman is not independent, the independent directors may select one of their members to be appointed lead independent director of the Board (Lead Independent Director) for such term as the independent directors may determine. The Lead Independent Director is responsible for chairing meetings of the independent directors and","filed_date":"2026-03-05","accession":"0001104659-26-024153","full_text":"https://origin.rootz.global/static/filing/0001104659-26-024153.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PROF","company":"Profound Medical Corp.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"ai_adoption","strength":96,"match_count":12,"context":"al outcomes, side effects and recovery time. *Customizable incision-free ablation of unrivalled variety of prostate indications.* Products TULSA-PRO *Clinical Studies* In March 2014, we completed enrollment and treatment of 30 patients in the TULSA multi-jurisdictional safety and precision study. Based on the trial results, in April 2016, Profound received a CE Certificate of Conformity for the TULSA","filed_date":"2025-03-07","accession":"0001410578-25-000300","full_text":"https://origin.rootz.global/static/filing/0001410578-25-000300.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PROF","company":"Profound Medical Corp.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":96,"match_count":12,"context":"could reasonably be expected to interfere with the exercise of the directors independent judgment. If the Chairman is not independent, the independent directors may select one of their members to be appointed lead independent director of the Board (Lead Independent Director) for such term as the independent directors may determine. The Lead Independent Director is responsible for chairing meetings of the independent directors and","filed_date":"2025-03-07","accession":"0001410578-25-000300","full_text":"https://origin.rootz.global/static/filing/0001410578-25-000300.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PROF","company":"Profound Medical Corp.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"platform_shift","strength":91,"match_count":2,"context":"protection in all jurisdictions where we intend to carry on business, including the United States, Canada, Japan, major European markets (e.g., Germany, France, U.K., Italy, Spain and Turkey) and the emerging markets (e.g., Brazil, Russia, India, and China). 16 [Table of Contents](#TOC) We also rely upon trade secrets, know-how and other proprietary, confidential information for the protection of our technology.","filed_date":"2025-03-07","accession":"0001410578-25-000300","full_text":"https://origin.rootz.global/static/filing/0001410578-25-000300.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PROF","company":"Profound Medical Corp.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_concentration","strength":91,"match_count":2,"context":"e, we have not hedged against risk associated with foreign exchange rate exposure. As we commercialize our approved products, in particular our TULSA-PRO system in the United States, we expect that a significant portion of our revenues, expenses, current assets and current liabilities will be denominated in United States dollars, Euros and other foreign currencies. Currently, our financial statements are expressed in United States","filed_date":"2025-03-07","accession":"0001410578-25-000300","full_text":"https://origin.rootz.global/static/filing/0001410578-25-000300.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PROF","company":"Profound Medical Corp.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_concentration","strength":81,"match_count":2,"context":"e, we have not hedged against risk associated with foreign exchange rate exposure. As we commercialize our approved products, in particular our TULSA-PRO system in the United States, we expect that a significant portion of our revenues, expenses, current assets and current liabilities will be denominated in United States dollars, Euros and other foreign currencies. Currently, our financial statements are expressed in United States","filed_date":"2026-03-05","accession":"0001104659-26-024153","full_text":"https://origin.rootz.global/static/filing/0001104659-26-024153.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PROF","company":"Profound Medical Corp.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":48,"match_count":6,"context":"rofound since June 2018. Dr. Rosenthal formerly served as director and Chair of the Compensation Committee for LivaNova PLC, a UK global medical technology company. Prior, Dr. Rosenthal served on the Cyberonics board of directors as a non-executive director and Chair of the Compensation Committee from January 2007 to October 2015. Since June 2010, Dr. Rosenthal has served as Professor of Practice in th","filed_date":"2025-04-22","accession":"0001171843-25-002369","full_text":"https://origin.rootz.global/static/filing/0001171843-25-002369.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PROF","company":"Profound Medical Corp.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":42,"match_count":4,"context":"a covenant waiver or replace or refinance our existing debt on favorable terms or at all, such default could materially adversely impact our results of operations and financial results and may have a material adverse effect on the trading price of our Common Shares. 21 [Table of Contents](#TOC) **Cash Flows** The following table summarizes our cash flows for each of the periods presented (in thousands): | | | | | | | |","filed_date":"2025-11-13","accession":"0001104659-25-111378","full_text":"https://origin.rootz.global/static/filing/0001104659-25-111378.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PROF","company":"Profound Medical Corp.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"platform_shift","strength":36,"match_count":2,"context":"protection in all jurisdictions where we intend to carry on business, including the United States, Canada, Japan, major European markets (e.g., Germany, France, U.K., Italy, Spain and Turkey) and the emerging markets (e.g., Brazil, Russia, India, and China). We also rely upon trade secrets, know-how and other proprietary, confidential information for the protection of our technology. We require all employees, co","filed_date":"2026-03-05","accession":"0001104659-26-024153","full_text":"https://origin.rootz.global/static/filing/0001104659-26-024153.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PROF","company":"Profound Medical Corp.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":18,"match_count":1,"context":"egal Proceedings. From time to time, we may be subject to legal proceedings. We are not currently a party to or aware of any proceedings that we believe will have, individually or in the aggregate, a material adverse effect on our business, financial condition or results of operations. Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management reso","filed_date":"2025-08-14","accession":"0001410578-25-001809","full_text":"https://origin.rootz.global/static/filing/0001410578-25-001809.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PROF","company":"Profound Medical Corp.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":18,"match_count":1,"context":"egal Proceedings. From time to time, we may be subject to legal proceedings. We are not currently a party to or aware of any proceedings that we believe will have, individually or in the aggregate, a material adverse effect on our business, financial condition or results of operations. Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management reso","filed_date":"2025-05-08","accession":"0001410578-25-001112","full_text":"https://origin.rootz.global/static/filing/0001410578-25-001112.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PROF","company":"Profound Medical Corp.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"margin_pressure","strength":16,"match_count":2,"context":"establish exclusive collaborative or licensing relationships with our competitors. Further, our industry is also subject to changing industry standards, market trends and customer preferences and to competitive pressures which can, among other things, necessitate revisions in pricing strategies, price reductions and reduced profit margins. Our success will depend, in part, on our ability to achieve technological sup","filed_date":"2026-03-05","accession":"0001104659-26-024153","full_text":"https://origin.rootz.global/static/filing/0001104659-26-024153.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PROF","company":"Profound Medical Corp.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"growth_inflection","strength":16,"match_count":2,"context":"wise, all amounts in this press release are expressed in U.S. dollars and are presented in accordance with U.S. generally accepted accounting principles (U.S. GAAP). **Business Highlights** - Q4-2025 revenue grew 43% year-over-year and 13% sequentially quarter-over-quarter to a record $6.0 million. - Profounds TULSA-PRO qualified sales pipeline also continues to grow, and currently stands at 110 new systems being","filed_date":"2026-03-05","accession":"0001171843-26-001362","full_text":"https://origin.rootz.global/static/filing/0001171843-26-001362.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PROF","company":"Profound Medical Corp.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"ai_adoption","strength":16,"match_count":2,"context":"erapies as SOC Past RCTs for localized Pca failed to recruit due to lack of equipoise (SPIRIT, SWOG - 8890, START, etc ) CAPTAIN is the first RCT in this space to successfully randomize to target enrollment Randomization continues to replace deallocations until 201 patients treated OBJECTIVE Compare the efficacy and quality of life outcomes of the TULSA procedure to robotic prostatectomy SUBJECTS 201","filed_date":"2025-04-29","accession":"0001171843-25-002561","full_text":"https://origin.rootz.global/static/filing/0001171843-25-002561.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PROF","company":"Profound Medical Corp.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"margin_pressure","strength":16,"match_count":2,"context":"establish exclusive collaborative or licensing relationships with our competitors. Further, our industry is also subject to changing industry standards, market trends and customer preferences and to competitive pressures which can, among other things, necessitate revisions in pricing strategies, price reductions and reduced profit margins. Our success will depend, in part, on our ability to achieve technological sup","filed_date":"2025-03-07","accession":"0001410578-25-000300","full_text":"https://origin.rootz.global/static/filing/0001410578-25-000300.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PROF","company":"Profound Medical Corp.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":16,"match_count":2,"context":"GAAP). **Business Highlights** - Q4-2024 revenue growth of 108% over Q4-2023. - During the fourth quarter, Profound made two key executive changes to further support growth; Mathieu Burtnyk, PhD, was promoted to President and Tom Tamberrino was appointed as Profounds new Chief Commercial Officer. - Profound also announced it had entered into non-exclusive collaboration with Siemens Healthineers designed to further exp","filed_date":"2025-03-07","accession":"0001171843-25-001319","full_text":"https://origin.rootz.global/static/filing/0001171843-25-001319.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PROF","company":"Profound Medical Corp.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"ai_adoption","strength":16,"match_count":2,"context":"sed by $444, or 7%, to $5,654 compared to $6,098 for the three months ended June 30, 2025. The decrease in R&D expenses was largely due to a reduction in clinical trial costs due to CAPTAIN trial enrollment completion. Offsetting these costs was an increased headcount, travel expenditures and higher consulting expenditures due to spending on R&D initiatives to reduce product costs and improve quality","filed_date":"2026-08-06","accession":"0001104659-26-092066","full_text":"https://origin.rootz.global/static/filing/0001104659-26-092066.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PROF","company":"Profound Medical Corp.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"ai_adoption","strength":16,"match_count":2,"context":"nt to the Employment Agreement, Mr. Fabian will be granted (i) 200,000 restricted share units under the Companys 2020 Amended and Restated Long Term Incentive Plan, vesting in three equal annual installments over three years, and (ii) options to purchase 475,000 common shares of the Company under the Companys Second Amended and Restated Share Option Plan, vesting over four years, with one-quarter ves","filed_date":"2026-09-03","accession":"0001171843-26-005868","full_text":"https://origin.rootz.global/static/filing/0001171843-26-005868.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PROF","company":"Profound Medical Corp.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":13,"match_count":1,"context":"egal Proceedings. From time to time, we may be subject to legal proceedings. We are not currently a party to or aware of any proceedings that we believe will have, individually or in the aggregate, a material adverse effect on our business, financial condition or results of operations. Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management reso","filed_date":"2026-08-06","accession":"0001104659-26-092066","full_text":"https://origin.rootz.global/static/filing/0001104659-26-092066.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PROF","company":"Profound Medical Corp.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":8,"match_count":1,"context":"ccessor is duly elected and qualified, or until his earlier death, resignation or removal. There are no arrangements or understandings between Mr. Baylis and any other person pursuant to which he was appointed as a director, and there are no family relationships between Mr. Baylis and any director or executive officer of the Company. There are no transactions to which the Company is a party and in which Mr. Baylis has a","filed_date":"2026-03-10","accession":"0001104659-26-025822","full_text":"https://origin.rootz.global/static/filing/0001104659-26-025822.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PROF","company":"Profound Medical Corp.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"platform_shift","strength":8,"match_count":1,"context":"d a year ago. Gross margin for the fourth quarter of 2025 was 67%, compared to 71% in the prior year period. The lower than usual fourth quarter 2025 gross margin was primarily due to product mix and new market introductory prices with international distributors in Saudi Arabia and Australia. Total operating expenses in the fourth quarter of 2025 were approximately $11.4 million, up marginally from $11.3 mi","filed_date":"2026-03-05","accession":"0001171843-26-001362","full_text":"https://origin.rootz.global/static/filing/0001171843-26-001362.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PROF","company":"Profound Medical Corp.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":8,"match_count":1,"context":"sclose personal information to any third party; and (v) use employee administrative, physical and technological safeguards to reasonably secure and protect personal information against loss, theft or unauthorized access, use or modification. It is expressly acknowledged and agreed that the Canadian Trustee may, in the course of providing services hereunder, collect or receive, use and disclose financial and other pe","filed_date":"2025-11-13","accession":"0001104659-25-111470","full_text":"https://origin.rootz.global/static/filing/0001104659-25-111470.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PROF","company":"Profound Medical Corp.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":8,"match_count":1,"context":"der of a Security for at least six months, or (d)either Trustee shall become incapable of acting or shall be adjudged a bankrupt or insolvent or a receiver of such Trustee or of its property shall be appointed or any public officer shall take charge or control of such Trustee or of its property or affairs for the purpose of rehabilitation, conservation or liquidation, then, in any such case, (i) the Company, by a Board Resoluti","filed_date":"2025-11-13","accession":"0001104659-25-111470","full_text":"https://origin.rootz.global/static/filing/0001104659-25-111470.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PROF","company":"Profound Medical Corp.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":8,"match_count":1,"context":"below set forth the number of votes cast for, against or withheld, for each matter voted on by the Companys shareholders. |  1. | Election of Directors |  | Each of the six nominees listed below was elected as Director of the Corporation to hold office until the Corporations next annual meeting of shareholders or until their successor is duly appointed. |  Nominee |  For |  % For |  Withheld |  % Withheld | | |  Ar","filed_date":"2025-05-14","accession":"0001171843-25-003194","full_text":"https://origin.rootz.global/static/filing/0001171843-25-003194.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PROF","company":"Profound Medical Corp.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"growth_inflection","strength":8,"match_count":1,"context":"ch consists of the sale of TULSA-PRO consumables, lease of capital equipment and services associated with extended warranties, and $820,000 from one-time sale of capital equipment. First quarter 2025 revenue increased 82% from $1.4 million in the same three-month period a year ago. Gross margin for the first quarter of 2025 was 71%, compared to 60% in the prior year period and 71% in the fourth quarter of 2024. Gross","filed_date":"2025-05-08","accession":"0001171843-25-002987","full_text":"https://origin.rootz.global/static/filing/0001171843-25-002987.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PROF","company":"Profound Medical Corp.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"ai_adoption","strength":8,"match_count":1,"context":"were 60-100cc; and 5% were over 100cc. - The Level 1 CAPTAIN (A Comparison of TULSA Procedure vs. Radical Prostatectomy in Participants with Localized Prostate Cancer) trial has completed patient enrollment and Profound expects to release available perioperative data from the trial during the upcoming American Urological Associations (AUA) 2025 annual meeting (April 26-29, 2025). 2024 marked the fina","filed_date":"2025-03-07","accession":"0001171843-25-001319","full_text":"https://origin.rootz.global/static/filing/0001171843-25-001319.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PROF","company":"Profound Medical Corp.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"growth_inflection","strength":8,"match_count":1,"context":"nsists of the sale of TULSA-PRO consumables, lease of capital equipment and services associated with extended warranties, and $1.5 million from one-time sale of capital equipment. Fourth quarter 2024 revenue increased 108% from $2.0 million in the same three-month period a year ago. Total operating expenses in the fourth quarter of 2024 were $11.3 million, compared with $9.8 million in the prior year period. The increa","filed_date":"2025-03-07","accession":"0001171843-25-001319","full_text":"https://origin.rootz.global/static/filing/0001171843-25-001319.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PROF","company":"Profound Medical Corp.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"ai_adoption","strength":8,"match_count":1,"context":"g expenses declined 16% year over year to approximately $13.0 million, primarily reflecting lower personnel, commercial, travel, insurance and CAPTAIN clinical trial costs following completion of enrollment. These reductions were partially offset by higher R&D investments focused on product cost reduction, quality improvements and manufacturing efficiencies. Second quarter 2026 net loss was approxima","filed_date":"2026-08-06","accession":"0001171843-26-005322","full_text":"https://origin.rootz.global/static/filing/0001171843-26-005322.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PROF","company":"Profound Medical Corp.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":8,"match_count":1,"context":"ngements of Certain Officers.** **Appointment of Interim Chief Financial Officer** On August 14, 2026, Profound Medical Corp. (the Company or Profound Medical) announced that Matthew Sobczyk has been appointed by the Board of Directors of the Company (the Board) to serve as the Interim Chief Financial Officer of the Company, effective as of the same date (the Appointment Date). Matthew Sobczyk, CPA, CA, age 42, has served in progr","filed_date":"2026-08-17","accession":"0001171843-26-005575","full_text":"https://origin.rootz.global/static/filing/0001171843-26-005575.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PROF","company":"Profound Medical Corp.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":8,"match_count":1,"context":"ompensatory Arrangements of Certain Officers.** ***Appointment of President*** On September 1, 2026, Profound Medical Corp. (the Company or Profound Medical) announced that Richard R. Fabian has been appointed by the Board of Directors of the Company (the Board) to serve as the President of the Company, effective as of the same date (the Appointment Date). Mr. Fabian succeeds Mathieu Burtnyk, PhD, who has shifted to the newly crea","filed_date":"2026-09-03","accession":"0001171843-26-005868","full_text":"https://origin.rootz.global/static/filing/0001171843-26-005868.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."}],"origin":{"leaf":"fa8d339f505c5d7ba8267c255449995d773320a3b95bd9978dbea0bba3c29c0e","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"a220b6a7c11e62e8a423d5ad4b3d7bd45da769d99ec67277de47e2921067aa17","parent":null,"source":"signal_search","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":5,"hourly_limit":500,"remaining":495,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}